Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,418 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluid administration Clear all

Conditions: Subarachnoid Hemorrhage, Acute Kidney Injury
Interventions: Sodium chloride /sodium acetate (16.4%), Sodium chloride (23.4%), PlasmaLyte; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Adrenoleukodystrophy
Interventions: glyceryl trierucate/glyceryl trioleate; Drug
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 18 Months to 8 Years · Male only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2014
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Age Related Macular Degeneration
Interventions: Not listed
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Surgical Incision
Interventions: DrySee® dressing with moisture detection, Tegaderm® + Pad transparent film dressing; Device
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Monroeville, Pennsylvania

Conditions: Urinary Tract Infections
Interventions: D-Mannose; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 20 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Wounds With Different Etiologies
Interventions: Swabs; Other
Lead sponsor: Systagenix Wound Management; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8
Interventions: Biospecimen Collection, Placebo Administration, Probiotic, Questionnaire Administration; Procedure · Drug · Dietary Supplement + 1 more
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Infertility
Interventions: Diafert; Device
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Encino, California • Clearwater, Florida • Hoffman Estates, Illinois + 6 more

Conditions: 1 Fluid Management
Interventions: Deltex CardioQ Probe; Device
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Status Epilepticus, Seizure, Epilepsy, Refractory Status Epilepticus, Medically Resistant Status Epilepticus
Interventions: Ketogenic diet; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 9
States / cities: Phoenix, Arizona • Honolulu, Hawaii • Chicago, Illinois + 6 more

Conditions: Cardiac Failure, Heart Failure, Congestive Heart Failure, Heart Failure, Congestive, Sleep Initiation and Maintenance Disorders, Chronic Insomnia, Disorders of Initiating and Maintaining Sleep, Fatigue, Pain, Depressive Symptoms, Sleep Disorders, Anxiety
Interventions: Cognitive Behavioral Therapy for Insomnia, Self-Management Education for Heart Failure; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Metastatic Breast Cancer
Interventions: PF-05280014, Paclitaxel, Herceptin®; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 4
States / cities: Plainville, Connecticut • Southington, Connecticut • Boca Raton, Florida + 1 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
Interventions: IgPro20 (low dose), Placebo, IgPro10, IgPro20 (high dose); Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more

Conditions: Epstein Barr Virus (EBV) Infection
Interventions: MVA-BN-EBV, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Acute Pancreatitis, Pancreatic Pseudocyst, Pancreatic Necrosis
Interventions: Endoscopic management of pancreatic fluid collections; Procedure
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Chronic Spontaneous Urticaria
Interventions: Ligelizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 1,033 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 39
States / cities: Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 36 more

Conditions: Electrical Status Epilepticus of Slow-Wave Sleep
Interventions: Epidiolex 100 mg/mL Oral Solution, Placebo; Drug · Other
Lead sponsor: Northwell Health; Other
Eligibility: 2 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Chemotherapy Adjuvant, Breast Cancer
Interventions: Dignicap System; Device
Lead sponsor: Target Health Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 4
States / cities: San Francisco, California • New York, New York • Winston-Salem, North Carolina

Conditions: Parkinson Disease
Interventions: Levodopameter; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Prevention
Interventions: Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel, Universal HEC Placebo Gel Formulation; Drug
Lead sponsor: Ian McGowan; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Los Angeles, California • Pittsburgh, Pennsylvania

Conditions: Sepsis, Neonatal Mortality, Antibiotic Resistant Infection, Enteric Infections, Serious Bacterial Infection
Interventions: chlorination for water disinfection and surface disinfection, infection prevention and control messaging; Device · Behavioral
Lead sponsor: University of California, Berkeley; Other
Eligibility: Not listed
Enrollment: 45,450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Advanced Cancer, Pleural Effusion
Interventions: Intrapleural catheter (IPC) drained, IPC Placement, Chest X-Ray; Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Abscess
Interventions: Standard of care breast abscess drainage, Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser illumination, Photodynamic therapy; Procedure · Drug · Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cigarette Smoker, Current Every Day Smoker
Interventions: Bronchoscopy with Bronchoalveolar Lavage, Cigarette, Electronic Cigarette, Laboratory Biomarker Analysis, Nicotine Replacement, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years to 52 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

A Low ChloridE hyperTonic Solution for Brain Edema

Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy

Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients

A Comparison Between Two Post-operative Dressings

Nutraceutical Efficacy for rUTI

Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

Evaluation of the Efficacy of Diafert in Predicting Embryos' Potential to Develop to the Blastocyst Stage

Trial With Deltex Cardio in Elective Bowel Resection Patients

Ketogenic Diet for Refractory Status Epilepticus

Insomnia Self-Management in Heart Failure

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults

Registry of Patients Undergoing Endoscopic Management of Pancreatic Fluid Collections

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).

Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia

Real-Time Levodopa Level Monitoring in Parkinson Disease

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates

Intrapleural Catheter Daily Versus Three Times a Week Drainage

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses

Bronchoscopy in Determining the Effect of E-Cigarette Smoking on Biomarkers in the Lungs